8-K Announcements
6Material company update
Apr 17, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Mar 10, 2026·SEC
Lixte Biotechnology Holdings, Inc.(LIXT)Earnings, Financials & Key Ratios
LIXT•NASDAQ
$7.19
Price updated Jun 27, 2026
AboutLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.Show more
- Revenue$0
- EBITDA-$6M-68.1%
- Net Income-$6M-67.6%
- EPS (Diluted)-1.26+20.8%
- ROE-101.95%+31.5%
LIXT Price & Volume
Lixte Biotechnology Holdings, Inc. (LIXT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Limited cash runway
"Lixte Biotechnology faces a precarious financial outlook characterized by a lack of revenue generation and an accelerating operational burn rate that reached $2.0 million in 2026Q1. The company's reliance on equity dilution and increasing debt obligations, which rose to $1.1 million in the most recent quarter, suggests significant long-term solvency risks. Investors should monitor the company's ability to secure non-dilutive funding, as the current cash runway of $3.3 million appears insufficient to support sustained clinical development."
Verdict Logic
the company's rapid depletion of cash reserves from $5.1 million in 2025Q4 to $3.3 million in 2026Q1, combined with a lack of revenue, presents an unsustainable risk profile for long-term investors.
LIXT Growth Metrics
Lixte Biotechnology Holdings, Inc. (LIXT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-118.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM22.07%
Return on Capital
10 Years-196.32%
5 Years-121.36%
3 Years-114.29%
Last Year-83.54%
Peers Comparison
Key metrics vs top competitors for Lixte Biotechnology Holdings, Inc. (LIXT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.19 | $78.29M | -5.71 | — | — | -101.95% | — | |
| $0.95 | $106.43M | -3.28 | — | — | — | — | |
| $0.15 | $2.33M | -0.06 | -15.77% | -183.93% | — | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $37.90 | $2.25B | -5.32 | 48.03% | -639.84% | -34.11% | — |
Compare LIXT vs Peers
Lixte Biotechnology Holdings, Inc. (LIXT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LIXT SEC Filings & Documents
Lixte Biotechnology Holdings, Inc. (LIXT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when LIXT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LIXT Frequently Asked Questions
Lixte Biotechnology Holdings, Inc. (LIXT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is LIXT profitable?
Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $7.3M for fiscal year 2025.
Dividend & Returns
What is LIXT's return on equity?
Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity (ROE) of -102.0%. Negative ROE indicates the company is unprofitable.
What is Lixte Biotechnology Holdings, Inc.'s free cash flow?
Lixte Biotechnology Holdings, Inc. (LIXT) had negative free cash flow of $4.4M in fiscal year 2025, likely due to heavy capital investments.